Quarterly ResultMay 13, 2026, 08:07 AM
Century Therapeutics Q1 Net Loss $(21.6M); Revenue $0
AI Summary
Century Therapeutics reported a net loss of $(21.6) million for the three months ended March 31, 2026, a significant decline from a net income of $76.6 million in the prior-year period, primarily due to zero collaboration revenue compared to $109.2 million in Q1 2025. The company also saw a decrease in R&D and G&A expenses. Despite the loss, the company raised $126.4 million from a PIPE offering, strengthening its financial position with total stockholders' equity increasing to $264.7 million.
Key Highlights
- Net loss was $(21.6) million in Q1 2026, compared to net income of $76.6 million in Q1 2025.
- Collaboration revenue was $0 in Q1 2026, down from $109.2 million in Q1 2025.
- Basic and diluted net loss per common share was $(0.11) in Q1 2026, versus $0.89 income in Q1 2025.
- Research and development expenses decreased to $17.1 million from $26.6 million year-over-year.
- General and administrative expenses decreased to $6.6 million from $8.4 million year-over-year.
- Net cash used in operating activities was $(25.3) million in Q1 2026.
- Raised $126.4 million from the issuance of common stock, warrants, and pre-funded warrants.
- Total stockholders' equity increased to $264.7 million as of March 31, 2026, from $158.9 million at Dec 31, 2025.